BR112021020391A2 - Linhagens de células produtoras projetadas e métodos para preparar e usar as mesmas - Google Patents

Linhagens de células produtoras projetadas e métodos para preparar e usar as mesmas

Info

Publication number
BR112021020391A2
BR112021020391A2 BR112021020391A BR112021020391A BR112021020391A2 BR 112021020391 A2 BR112021020391 A2 BR 112021020391A2 BR 112021020391 A BR112021020391 A BR 112021020391A BR 112021020391 A BR112021020391 A BR 112021020391A BR 112021020391 A2 BR112021020391 A2 BR 112021020391A2
Authority
BR
Brazil
Prior art keywords
cell lines
methods
preparing
producer cell
engineered
Prior art date
Application number
BR112021020391A
Other languages
English (en)
Portuguese (pt)
Inventor
R Tiernan Aubrey
Nicholas Richards
Original Assignee
Ultragenyx Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ultragenyx Pharmaceutical Inc filed Critical Ultragenyx Pharmaceutical Inc
Publication of BR112021020391A2 publication Critical patent/BR112021020391A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BR112021020391A 2019-04-12 2020-04-09 Linhagens de células produtoras projetadas e métodos para preparar e usar as mesmas BR112021020391A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962833548P 2019-04-12 2019-04-12
US201962839207P 2019-04-26 2019-04-26
US202062979483P 2020-02-21 2020-02-21
PCT/US2020/027489 WO2020210507A1 (en) 2019-04-12 2020-04-09 Engineered producer cell lines and methods of making and using the same

Publications (1)

Publication Number Publication Date
BR112021020391A2 true BR112021020391A2 (pt) 2022-02-08

Family

ID=70465550

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021020391A BR112021020391A2 (pt) 2019-04-12 2020-04-09 Linhagens de células produtoras projetadas e métodos para preparar e usar as mesmas

Country Status (15)

Country Link
US (2) US12018288B2 (cg-RX-API-DMAC7.html)
EP (2) EP3953458A1 (cg-RX-API-DMAC7.html)
JP (2) JP7560475B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210152514A (cg-RX-API-DMAC7.html)
CN (1) CN113966395B (cg-RX-API-DMAC7.html)
AU (1) AU2020270960B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021020391A2 (cg-RX-API-DMAC7.html)
CA (1) CA3136246A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021013699A2 (cg-RX-API-DMAC7.html)
IL (1) IL287106A (cg-RX-API-DMAC7.html)
MX (1) MX2021012489A (cg-RX-API-DMAC7.html)
PH (1) PH12021552577A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202110904PA (cg-RX-API-DMAC7.html)
TW (1) TWI859216B (cg-RX-API-DMAC7.html)
WO (1) WO2020210507A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12054738B2 (en) 2020-07-30 2024-08-06 Shape Therapeutics Inc. Stable cell lines for inducible production of rAAV virions
JP2024531138A (ja) 2021-08-11 2024-08-29 ウルトラジェニックス ファーマシューティカル インコーポレイテッド 筋ジストロフィーを処置するための組成物および方法
JP2024537896A (ja) 2021-10-18 2024-10-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アデノウイルス随伴ウイルスポリヌクレオチドを含む真核細胞
AR127674A1 (es) 2021-10-18 2024-02-21 Regeneron Pharma Células de mamífero que comprenden genes cas9 integrados para producir sitios de integración estables, y células de mamífero que comprenden sitios de integración estables y otros sitios
WO2023077078A1 (en) 2021-10-29 2023-05-04 Ultragenyx Pharmaceutical Inc. Engineered cell lines for increased production of recombinant adeno-associated virus (raav)
CA3245327A1 (en) 2022-03-07 2023-09-14 Ultragenyx Pharmaceutical Inc. MODIFIED BATCH-BASED AAV PRODUCTION SYSTEMS AND PROCESSES
CN122161940A (zh) * 2023-10-12 2026-06-05 塞维克制药有限责任公司 影响重组aav生产的细胞因子
WO2025226558A1 (en) 2024-04-22 2025-10-30 Ultragenyx Pharmaceutical Inc. Multi-step filtration and clarification methods for recombinant adeno-associated virus purification
WO2026078664A1 (en) 2024-10-10 2026-04-16 Instituto De Biologia Experimental E Tecnológica (Ibet) Transcription factor enhancing recombinant adeno-associated virus production, products, methods and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5387484A (en) 1992-07-07 1995-02-07 International Business Machines Corporation Two-sided mask for patterning of materials with electromagnetic radiation
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
WO1996017947A1 (en) 1994-12-06 1996-06-13 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant aav vectors
US5741683A (en) 1995-06-07 1998-04-21 The Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US5688676A (en) 1995-06-07 1997-11-18 Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
CA2270285A1 (en) 1996-12-18 1998-06-25 Targeted Genetics Corporation Aav split-packaging genes and cell lines comprising such genes for use in the production of recombinant aav vectors
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
CA2995542A1 (en) * 1997-09-05 1999-03-11 Genzyme Corporation Methods for generating high titer helper-free preparations of recombinant aav vectors
WO2000024916A1 (en) 1998-10-27 2000-05-04 Crucell Holland B.V. Improved aav vector production
DE19905501B4 (de) 1999-02-10 2005-05-19 MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels
US7510872B2 (en) 2003-02-26 2009-03-31 Nationwide Children's Hospital Recombinant adeno-associated virus production
ATE530667T1 (de) 2005-05-27 2011-11-15 Evotec Neurosciences Gmbh Kcnn3 als diagnostisches und therapeutisches target für alzheimer-krankheit
PT3272872T (pt) 2005-10-20 2020-06-26 Uniqure Ip Bv Vetores aav melhorados produzidos em células de insetos
US8188060B2 (en) 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
BR112015018493A2 (pt) 2013-02-05 2017-08-22 Univ Georgia Linhagens celulares para produção de vírus e métodos de uso
CN104592364B (zh) * 2013-10-30 2018-05-01 北京大学 定点突变和定点修饰的腺相关病毒、其制备方法及应用
GB201401707D0 (en) 2014-01-31 2014-03-19 Sec Dep For Health The Adeno-associated viral vectors
US20160319277A1 (en) 2015-01-28 2016-11-03 The Johns Hopkins University METHODS OF IMPROVED PROTEIN PRODUCTION USING MIRNAs AND SIRNAs
ES2938833T3 (es) 2016-03-28 2023-04-17 Ultragenyx Pharmaceutical Inc Métodos de inactivación térmica de adenovirus
EP3484493A4 (en) 2016-07-12 2019-12-25 Ultragenyx Pharmaceutical Inc. USE OF GLUCOCORTICOID ANALOGS TO INCREASE THE PERFORMANCE OF RECOMBINANT ADENO-ASSOCIATED VIRUSES
ES3012649T3 (en) 2016-10-14 2025-04-09 Ultragenyx Pharmaceutical Inc Use of tonicifying agents to enhance recombinant adeno-associated virus yield
US20200048641A1 (en) 2017-03-22 2020-02-13 Ultragenyx Pharmaceutical Inc. Methods for enhancing yield of recombinant adeno-associated virus
EP3601581B1 (en) 2017-03-22 2025-04-30 Ultragenyx Pharmaceutical Inc. CELL CULTURE METHODS INVOLVING HDAC INHIBITORS OR REP PROTEINS
EP3621734A4 (en) 2017-05-09 2020-12-30 Ultragenyx Pharmaceutical Inc. MODULAR PROCESS FOR THE PRODUCTION OF TRANSFECTION REAGENTS
CA3088538A1 (en) 2018-01-19 2019-07-25 The University Of North Carolina At Chapel Hill Methods and compositions for inhibition of innate immune response associated with aav transduction
US12577539B2 (en) 2019-04-26 2026-03-17 The Regents Of The University Of California Cells for enhanced production of adeno-associated virus
WO2023077078A1 (en) * 2021-10-29 2023-05-04 Ultragenyx Pharmaceutical Inc. Engineered cell lines for increased production of recombinant adeno-associated virus (raav)

Also Published As

Publication number Publication date
MX2021012489A (es) 2021-11-12
US12018288B2 (en) 2024-06-25
WO2020210507A1 (en) 2020-10-15
EP3953458A1 (en) 2022-02-16
AU2020270960A1 (en) 2021-11-04
SG11202110904PA (en) 2021-10-28
JP2022526646A (ja) 2022-05-25
EP4603579A3 (en) 2025-12-10
TW202104593A (zh) 2021-02-01
CA3136246A1 (en) 2020-10-15
PH12021552577A1 (en) 2022-04-04
US20200325455A1 (en) 2020-10-15
CN113966395A (zh) 2022-01-21
CO2021013699A2 (es) 2021-10-29
US20240376440A1 (en) 2024-11-14
IL287106A (en) 2021-12-01
TWI859216B (zh) 2024-10-21
JP2024107295A (ja) 2024-08-08
AU2020270960B2 (en) 2026-01-29
KR20210152514A (ko) 2021-12-15
EP4603579A2 (en) 2025-08-20
CN113966395B (zh) 2025-07-04
JP7706607B2 (ja) 2025-07-11
JP7560475B2 (ja) 2024-10-02

Similar Documents

Publication Publication Date Title
PH12021552577A1 (en) Engineered producer cell lines and methods of making and using the same
SA520420332B1 (ar) الأجسام المضادة لمكون مضاد للمتمم وطرق استخدامها
BR112021021295A2 (pt) Proteínas recombinantes do leite e composições compreendendo as mesmas
SA520420518B1 (ar) تبديل الانتحاء النسيجي للفَيروسات المُرتَبِط بالفَيروس الغُدِّيّ
EA202091712A1 (ru) МОДИФИЦИРОВАННЫЙ КАПСИДНЫЙ БЕЛОК rAAV ДЛЯ ГЕННОЙ ТЕРАПИИ
BR112020002012A8 (pt) Anticorpos anti-cd39, composições que compreendem anticorpos anti-cd39 e métodos de utilização de anticorpos anti-cd39
BR112017000939A2 (pt) tratamento de câncer usando um receptor antigênico quimérico de cll-1
MX2021012205A (es) Anticuerpos de cadena pesada que se unen al psma.
MX2019012223A (es) Anticuerpos anti-cd137 y metodos de uso de los mismos.
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
BR112022001359A2 (pt) Método e composição para anticorpos anti-cd73 e variantes
BR112018012180A2 (pt) vírus de codificação de um anticorpo ou fragmento de complexo anti-tcr
MX2021015761A (es) Polipeptidos.
UY38542A (es) Neoantígenos próstaticos, vacunas y composiciones farmacéuticas que los contienen
MX380631B (es) Vectores de adenovirus canino
BR112019004711A2 (pt) receptores de antígeno quiméricos compreendendo domínios de fibronectina tipo iii específicos para bcma e usos dos mesmos
BR112018011122A2 (pt) antígenos, vetores, composições, e métodos de utilização para o vírus da imunodeficiência humana dos mesmos
MX2025008949A (es) Arni variante
BR112022001912A2 (pt) Composições celulares compreendendo vetores virais e métodos de tratamento
ECSP19026593A (es) Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos
BR112020003976A8 (pt) Vírus adeno-associado (aav) com domínio fosfolipase modificado
SV2016005264A (es) Proteínas de fusión tatk-cdkl5, composiciones, formulaciones y uso de estas
BR112019005516A2 (pt) novo sítio de inserção do ehv orf70
BR112022000835A2 (pt) Composição e métodos para preparar produto de hemicelulose de borra de café gasta
BR112023022367A2 (pt) Anticorpos anti-tigit e métodos de uso dos mesmos

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]